Royalty Pharma Raises 2026 Portfolio Receipts Forecast to $3.5 Billion-$3.55 Billion

Bitget2026/11/04 12:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Royalty Pharma raised its 2026 portfolio receipts forecast to $3.5 billion-$3.55 billion from $3.4 billion-$3.5 billion, reflecting strong portfolio performance.
Royalty receipts growth is now expected at 10%-11%, up from 7%-10% previously.
Operating and professional costs are projected at approximately 5.5%-6% of portfolio receipts, versus 5.5%-6.5% previously.
Milestones and other contractual receipts are expected to fall to approximately $65 million from $128 million in 2025.
Third-quarter portfolio receipts rose 9% to $890 million; year-to-date royalty receipts increased 12% to $2.54 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Royalty Pharma Raises 2026 Portfolio Receipts Forecast to $3.5 Billion-$3.55 Billion

You may also like

Crypto prices